COMP <GO>
GH vs LLY // PIOTROSKI F-SCORE QUALITY
Guardant Health Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GH 3
— LLY 11
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
piotroski-score
6/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 83.64% | -19.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 32.36% | -49.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 2.30% | -3.24 | LLY | /fcf-yield <GO> |
| Operating Margin | -44.50% | 40.21% | -84.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 31.90% | -74.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 45.51% | -12.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 9.29 | -3.85 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | GH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 77.9 | -20.63 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.51 | +0.36 | GH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 26.3x | -7.25 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | LLY REV | GH GROSS % | LLY GROSS % | GH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $65.18B | 64.5% | 83.0% | -$233.1M | $16.81B |
| FY 2024 | $739.0M | $45.04B | 60.8% | 81.3% | -$274.9M | $8.82B |
| FY 2023 | $563.9M | $34.12B | 44.0% | 79.3% | -$350.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
LLY // BETA 0.51